April 9 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1, MULTIPLE ASCENDING DOSE LUMINA TRIAL OF AMX0114 IN PEOPLE LIVING WITH AMYOTROPHIC LATERAL SCLEROSIS
AMYLYX PHARMACEUTICALS INC: AMYLYX EXPECTS EARLY COHORT DATA FROM LUMINA THIS YEAR
Source text: ID:nBw8x7L5Wa
Further company coverage: AMLX.O
(((( Reuters.briefs@thomsonreuters.com ;));))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。